You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨嘉和生物-B(6998.HK)大漲近9% 國家藥監局批准兩項GB491三期臨牀試驗臨牀試驗申請
格隆匯 07-21 13:54
格隆匯7月21日丨嘉和生物-B(6998.HK)大漲近9%,報16.4港元,總市值81億港元。嘉和生物昨日公吿,公司已收到國家藥品監督管理局同意兩項GB491三期臨牀試驗的臨牀試驗申請。GB491為一款用於治療乳腺癌的高選擇性口服型CDK4/6抑制劑。公司於2020年6月向G1Therapeutics,Inc.取得若干亞太地區(不包括日本)的GB491專有權許可。GB491顯示出了良好的安全性,可能成為潛在的同類最佳CDK4/6候選藥物。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account